Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Glactone: ProSTATe stopper

Glactone's covalent STAT3 inhibitor arrests castration-resistant prostate cancer

Glactone Pharma AB is developing small molecule inhibitors of a mitogenic transcription factor that is overactive in castration-resistant prostate cancer and other solid tumors. The company has mechanistic evidence that its derivatives of the fungal metabolite galiellalactone directly and irreversibly block the activity of STAT3, and could be more bioavailable and better tolerated than more advanced compounds going after the target.

STAT3 (signal transducer and activator of transcription 3) is on the receiving end of the JAK/STAT signaling pathway, which is constitutively active in

Read the full 834 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE